Incyte plans Phase III trial of blood cancer drug as potential Covid-19 cytokine storm therapy
The company said it is working with the FDA to start a Phase III study of Jakafi in Covid-19-associated cytokine storm, which may be behind severe disease in some patients and for which JAK inhibitors have been suggested as a possible therapeutic option.